Project Grant HT94252410077
Award Date
3/1/24
Completion Date
2/29/28
Dollars Obligated
$2.8M
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
New York, NY 10065, USA
Similar Awards
The federal Project Grant award of $923,805.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant will fund the "Systematic Functional Dissection of Cancer Cell States in Lung Tumors" research project at the Sloan-Kettering Institute for Cancer Research in New York, NY. The project aims to advance understanding of cancer cell biology and develop novel therapeutic approaches for lung cancer, with...
This federal Project Grant award for $704,000.00, awarded by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), supports research by the Sloan-Kettering Institute for Cancer Research in New York, NY. The research aims to investigate the role of the NF-I/A transcription factor in regulating fatty acid metabolism in kidney cancer. This multi-year project will run from September 1, 2024 to August 31, 2028. As the prime grantee, the Sloan-Kettering...
The federal Project Grant award of $924,001.00 was provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research by the Sloan-Kettering Institute for Cancer Research to investigate the cellular and molecular origins of non-small cell lung cancer (NSCLC) brain metastasis. The research aims to enhance understanding of the mechanisms driving NSCLC brain metastasis, with the goal of developing innovative therapeutic...
The federal Project Grant award, totaling $384,342.00, was provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) to the Sloan-Kettering Institute For Cancer Research, a non-profit organization in New York, NY. The award, effective June 15, 2024 through June 14, 2027, supports the development of generalizable and reliable AI for early detection of melanoma. Through this funding, the Sloan-Kettering Institute For Cancer Research will...
Sloan-Kettering Institute For Cancer Research was awarded a $796,500 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) for the period of July 15, 2023 through July 14, 2026. The grant will support research to develop novel tools to improve responses to DNA-damaging therapeutics in metastatic breast cancer. As the prime recipient, Sloan-Kettering Institute For Cancer Research will leverage its expertise in cancer biology,...
This federal Project Grant award of $708,000.00 provided by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420) supports research conducted by the Sloan-Kettering Institute for Cancer Research, a non-profit organization located in New York, NY. The research project is focused on investigating the "Prevalence and Biologic Impact of FGFR3 Genomic Alterations in Bladder Cancer". The 2-year award period runs from September 15, 2023 to...
The federal Project Grant award, issued by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420), provides $1,944,610.00 to the Sloan-Kettering Institute for Cancer Research to conduct research on understanding tumorigenesis and identifying therapeutic targets in CDK12-mutant prostate cancer. The 3-year project, running from April 1, 2025 to March 31, 2028, aims to advance the scientific understanding and treatment of this specific form of prostate...
The Defense Health Agency awarded a $5.18 million project grant to the Sloan-Kettering Institute For Cancer Research to support research exploiting epigenetic vulnerabilities in breast cancers with chromosomal instability. The grant is part of the Military Medical Research and Development program (CFDA 12.420), which aims to transform military and public health care through innovative biomedical research and investigate medical solutions for battlefield wounds. Over a four-year period from May...
This $176,000 Project Grant award from the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research by the Sloan-Kettering Institute for Cancer Research to investigate the interactions of mitochondrially encoded complex I mutations with hypoxia and antitumor immune response in chromophobe renal cell carcinoma. The research aims to further the understanding of cancer biology and potential therapeutic approaches, with a focus on conditions...
The Sloan-Kettering Institute for Cancer Research was awarded a $707,346 Project Grant from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420). This 3-year grant, effective September 1, 2024, supports Sloan-Kettering's cancer research initiatives, including investigations into the tumor microenvironment, mechanisms of metastasis, epigenetic alterations in cancer, resistance to cancer therapies, aging-related biology, and hematologic malignancies....